Viewing Study NCT00631332


Ignite Creation Date: 2025-12-24 @ 9:54 PM
Ignite Modification Date: 2025-12-25 @ 7:32 PM
Study NCT ID: NCT00631332
Status: COMPLETED
Last Update Posted: 2017-11-06
First Post: 2008-02-28
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Women's Health Initiative Study of Cognitive Aging
Sponsor: Wake Forest University
Organization:

Study Overview

Official Title: Effects of Hormone Replacement Therapy on Cognitive Aging: Women's Health Initiative Study of Cognitive Aging (WHISCA)
Status: COMPLETED
Status Verified Date: 2017-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: WHISCA
Brief Summary: The Women's Health Initiative Study of Cognitive Aging (WHISCA) is a two-armed, randomized, placebo controlled, clinical trial designed to assess the efficacy of postmenopausal hormone therapy (HT) on age related changes in specific cognitive functions.
Detailed Description: WHISCA is an ancillary study to the Women's Health Initiative (WHI) and the WHI Memory Study (WHIMS) and has enrolled 2303 women aged 66 to 84 years who did not meet the criteria for dementia. WHISCA is investigating the effects of hormone therapy on rates of change over time in memory, other aspects of cognition (language, attention, spatial ability), motor function, and mood.

Objectives

* Does HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older?
* What is the rate of change in memory and other cognitive abilities in women receiving HT compared to women receiving placebo?
* Does the addition of progesterone to HT modify the effects of estrogen on memory and other cognitive abilities?

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: